A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Anthony Elias,  MD

Anthony Elias, MD

Study ID

Protocol Number: 22-0510

More information available at ClinicalTrials.gov: NCT05076591

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers